SLC17A4 as a Drug Target: An Overview (G10050)

Target Name: SLC17A4

NCBI ID: G10050

SLC17A4

SLC17A4 as a Drug Target: An Overview

The search for new drug targets and biomarkers plays a crucial role in modern drug discovery and precision medicine. One potential candidate that has gained significant attention in recent years is the SLC17A4 gene. This gene encodes a protein, also known as sodium-dependent phosphate transport protein 3 or NPT3, which is responsible for transporting inorganic phosphate across cellular membranes. In this article, we will explore the significance of SLC17A4 as a drug target and biomarker in various diseases and therapeutic interventions.

Understanding the Role of SLC17A4

SLC17A4 is primarily expressed in tissues associated with phosphate homeostasis, including the kidneys, intestines, and bones. The protein encoded by this gene is known to regulate phosphate levels in both the extracellular and intracellular compartments. Dysfunction of SLC17A4 has been linked to several pathological conditions, making it a potential target for therapeutic intervention.

SLC17A4 and Disorders of Phosphate Balance

Phosphate plays a vital role in many biological processes, such as bone mineralization, energy metabolism, and cellular signaling. Imbalances in phosphate levels have been associated with numerous diseases, including hypophosphatasia, X-linked hypophosphatemic rickets, and tumor-induced osteomalacia. In these conditions, SLC17A4 dysregulation contributes to abnormal phosphate handling, leading to clinical manifestations. Targeting SLC17A4 may provide a promising approach to restore phosphate homeostasis in these disorders.

SLC17A4 in Kidney Disease and Drug Development

The kidneys play a crucial role in phosphate homeostasis by regulating renal phosphate reabsorption. Studies have shown that dysregulation of SLC17A4 in the kidneys is associated with renal phosphate wasting, a hallmark feature of certain kidney diseases, such as hereditary hypophosphatemic rickets with hypercalciuria and Fanconi syndrome. Developing drugs that modulate SLC17A4 activity in the kidneys may help restore renal phosphate reabsorption and improve phosphate balance in these patients.

Biomarker Potential of SLC17A4

In addition to its role as a drug target, SLC17A4 also shows promise as a biomarker for various diseases. Research has shown that SLC17A4 expression levels can be altered in certain cancers, such as prostate cancer and breast cancer. Detecting changes in SLC17A4 expression may enable early diagnosis, prognosis, and monitoring of disease progression. Moreover, SLC17A4 could serve as a target for developing targeted therapies against these cancers.

Current Approaches in Targeting SLC17A4

Efforts to target SLC17A4 for therapeutic interventions are still in their early stages, but several interesting strategies have emerged. One approach involves the development of small molecule inhibitors that can selectively block SLC17A4 activity, thereby reducing phosphate transport. Preclinical studies have shown the potential of these inhibitors in modifying phosphate balance. However, more research is needed to assess their safety and efficacy in human trials.

Challenges and Future Perspectives

Despite the promising potential of SLC17A4 as a drug target and biomarker, there are several challenges that need to be addressed. Firstly, gaining a deeper understanding of the precise mechanisms underlying SLC17A4 regulation and its interactions with other molecules is crucial. Additionally, the development of selective and effective drugs targeting SLC17A4 poses significant challenges due to the complexity of the phosphate transport system. Nevertheless, continued research and advancements in drug discovery techniques hold great promise for exploiting SLC17A4 as a therapeutic target in the future.

In conclusion, SLC17A4 represents a promising drug target and biomarker in various diseases associated with phosphate imbalance. Understanding its role in phosphate homeostasis and developing targeted therapeutic interventions may lead to improved treatment options and personalized medicine. Further research and collaborations between scientists and clinicians will be pivotal in harnessing the full potential of SLC17A4 in the fight against diseases driven by phosphate dysregulation.

Protein Name: Solute Carrier Family 17 Member 4

Functions: Acts as a membrane potential-dependent organic anion transporter, the transport requires a low concentration of chloride ions. May be involved in urate extrusion from the intestinal duct. May recognize hydrophilic anionic drugs such as aspirin, salicylate, and ibuprofen as substrates. Able to actively transport inorganic phosphate into cells via Na(+) cotransport (in vitro)

The "SLC17A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC17A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets